Metabolic Acidosis; Critically Ill Patients; Organ DysfunctionNCT04953013
Risk Potential for Organ Dysfunction Associated With Sodium Bicarbonate Therapy (SBT) in Critically Ill Patients
An observational study of Metabolic Acidosis; Critically Ill Patients; Organ Dysfunction, run by Peking University Third Hospital at 1 site in China.
Trial summary
This study aimed to investigate whether hemodynamic status before SBT contributed to the effect of sodium bicarbonate infusion on the risk of neonatal organ dysfunction and mortality in critically ill patients with early metabolic acidosis in ICU. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Metabolic Acidosis; Critically Ill Patients; Organ Dysfunction
- What is being tested?
- sodium bicarbonate
- How many people
- 664 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2019to 1 Sep 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: We obtained data from the MIMIC-III. The newest version of MIMIC-III, v. 1.4, integrates 61,532 patients admitted to the ICUs of Beth Israel Deaconess Medical Center in Boston, Massachusetts.
Who may be able to join
- (1) pH≤7.3; (2) BE≤-8, or HCO3- < 20 mmol/L if BE was missing; and (3) PaCO2< 50 mmHg, or without chronic obstructive pulmonary disease (COPD) in discharge diagnoses if PaCO2 was unavailable.
Who cannot join
- (1) age 16 or under; (2) diabetes insipidus ; (3) comorbidity of peripheral paralysis; (4) ICU stay over 100 days; (5) SBT was initiated before ICU admission , later than 48 hours after ICU admission or after a record of order for renal replacement therapy (RRT); and (6) death within the first 24 hours after ICU admission.
Trial locations and contacts
1 site in 1 country.
China1 site
Critical Care Medicine Department
Beijing, Beijing Municipality, 100191
About this study
This study aimed to investigate whether hemodynamic status before SBT contributed to the effect of sodium bicarbonate infusion on the risk of neonatal organ dysfunction and mortality in critically ill patients with early metabolic acidosis in ICU.
Read the detailed description
Study Population We obtained data from the MIMIC-III. The newest version of MIMIC-III, v. 1.4, integrates 61,532 patients admitted to the ICUs of Beth Israel Deaconess Medical Center in Boston, Massachusetts.
Our study included patients with severe metabolic acidosis within 48 hours after ICU admission who fulfilled all of the following criteria: (1) pH≤7.3; (2) BE≤-8, or HCO3- < 20 mmol/L if BE was missing; and (3) PaCO2< 50 mmHg, or without chronic obstructive pulmonary disease (COPD) in discharge diagnoses if PaCO2 was unavailable. The lowest values of pH, BE, and HCO3- and the highest value of PaCO2 were selected when there were multiple measurements. We defined a composite of newly "developed or exacerbated organ dysfunction" (d/eOD) as a net increase in Sequential Organ Failure Assessment (SOFA) score ≥2 of at least one organ within 7 days of ICU admission over the baseline (SOFA score in the first 24 hours). Hemodynamic status during the initial resuscitation was defined as hemodynamic improvement, hemodynamic worsening and unchanged hemodynamics.
Variables Characteristic data of patients were extracted, including age and sex; category of diseases (surgical vs medical), history of comorbidity and whether cardiopulmonary resuscitation (CPR) was experienced; and diagnosis of sepsis, shock and AKI. Supportive interventions such as mechanical ventilation (MV) and RRT were recorded. Fluid balances at 24 hours and 48 hours after ICU admission and the total SB dosage administered within the first 48 hours were extracted. The SOFA score including each component was calculated every 24 hours if data were available. The Simplified Acute Physiology Score II (SAPSII) was calculated within the first 24 hours after ICU admission.
Laboratory variables included pH, actual bicarbonate (AB), base excess (BE), PaO2, PaCO2, hematocrit (Hct), hemoglobin (Hb), lactate concentration and electrolytes such as [Na+], [K+], and [Cl-]. We also calculated the anion gap (AG) by the formula AG=[Na+] + [K+] - [Cl-] - [HCO3-] .
A composite of newly d/eOD within 7 days of ICU admission was used as the primary outcome of this study. The secondary outcome was 28-day mortality.
Statistical Analysis Propensity score matching (PSM) was applied to minimize either selection biases or potential confounders for SBT. Continuous variables are expressed as the mean (standard deviation) or median (upper quantile, lower quantile), and a t-test or the Wilcoxon-test was used to compare the differences between groups. Categorical variables are depicted as the number of groups (the number of percentages), and the chi-squared test or Fisher's exact test was applied.Univariate and multivariat logistic regression and Cox regression were used to evaluate the effectiveness of SBT.
All statistical analyses were performed by R (version 3.6.1). A p value less than 0.05 was indicative of statistical significance.
- Being tested
- sodium bicarbonate
- Medical subject headings
- Acidosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sodium bicarbonateDrug
Drug exposure
| Study group | Role | What they receive |
|---|---|---|
| sodium bicarbonate group | Sodium bicarbonate was initiated within 48 hours after ICU admission. Receives: Drug: sodium bicarbonate | |
| non-sodium bicarbonate group | Patients were not infused with sodium bicarbonate. |
What is being measured
The primary outcome is the main question the study is designed to answer.
newly developed or exacerbated organ dysfunction
We defined a composite of newly "developed or exacerbated organ dysfunction" (d/eOD) as a net increase in Sequential Organ Failure Assessment (SOFA) score ≥2 of at least one organ within 7 days of ICU admission over the baseline (SOFA score in the first 24 hours).
Measured: The duration of the database covers from June 2001 to October 2012.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2021
- Study start1 Aug 2019
- Primary completion1 Feb 2020
- Study completion1 Sep 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolic Acidosis; Critically Ill Patients; Organ DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 664 participants (actual)
Sponsor and investigators
- Lead sponsor
- Peking University Third Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04953013
- Sponsor's protocol ID
- LM2020046
- Status last verified
- Jun 2021
- First submitted
- 29 Jun 2021
- Last updated
- 7 Jul 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk Potential for Organ Dysfunction Associated With Sodium Bicarbonate Therapy (SBT) in Critically Ill Patients
- ClinicalTrials.gov ID
- NCT04953013
- Acronym / sponsor ID
- LM2020046
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 664 participants (actual)
- Lead sponsor
- Peking University Third HospitalUniversity, hospital or other
- Study start
- 1 Aug 2019 (actual)
- Primary completion
- 1 Feb 2020 (actual)
- Study completion
- 1 Sep 2020 (actual)
- First posted
- 7 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to investigate whether hemodynamic status before SBT contributed to the effect of sodium bicarbonate infusion on the risk of neonatal organ dysfunction and mortality in critically ill patients with early metabolic acidosis in ICU.
Detailed description
Study Population We obtained data from the MIMIC-III. The newest version of MIMIC-III, v. 1.4, integrates 61,532 patients admitted to the ICUs of Beth Israel Deaconess Medical Center in Boston, Massachusetts.
Our study included patients with severe metabolic acidosis within 48 hours after ICU admission who fulfilled all of the following criteria: (1) pH≤7.3; (2) BE≤-8, or HCO3- < 20 mmol/L if BE was missing; and (3) PaCO2< 50 mmHg, or without chronic obstructive pulmonary disease (COPD) in discharge diagnoses if PaCO2 was unavailable. The lowest values of pH, BE, and HCO3- and the highest value of PaCO2 were selected when there were multiple measurements. We defined a composite of newly "developed or exacerbated organ dysfunction" (d/eOD) as a net increase in Sequential Organ Failure Assessment (SOFA) score ≥2 of at least one organ within 7 days of ICU admission over the baseline (SOFA score in the first 24 hours). Hemodynamic status during the initial resuscitation was defined as hemodynamic improvement, hemodynamic worsening and unchanged hemodynamics.
Variables Characteristic data of patients were extracted, including age and sex; category of diseases (surgical vs medical), history of comorbidity and whether cardiopulmonary resuscitation (CPR) was experienced; and diagnosis of sepsis, shock and AKI. Supportive interventions such as mechanical ventilation (MV) and RRT were recorded. Fluid balances at 24 hours and 48 hours after ICU admission and the total SB dosage administered within the first 48 hours were extracted. The SOFA score including each component was calculated every 24 hours if data were available. The Simplified Acute Physiology Score II (SAPSII) was calculated within the first 24 hours after ICU admission.
Laboratory variables included pH, actual bicarbonate (AB), base excess (BE), PaO2, PaCO2, hematocrit (Hct), hemoglobin (Hb), lactate concentration and electrolytes such as [Na+], [K+], and [Cl-]. We also calculated the anion gap (AG) by the formula AG=[Na+] + [K+] - [Cl-] - [HCO3-] .
A composite of newly d/eOD within 7 days of ICU admission was used as the primary outcome of this study. The secondary outcome was 28-day mortality.
Statistical Analysis Propensity score matching (PSM) was applied to minimize either selection biases or potential confounders for SBT. Continuous variables are expressed as the mean (standard deviation) or median (upper quantile, lower quantile), and a t-test or the Wilcoxon-test was used to compare the differences between groups. Categorical variables are depicted as the number of groups (the number of percentages), and the chi-squared test or Fisher's exact test was applied.Univariate and multivariat logistic regression and Cox regression were used to evaluate the effectiveness of SBT.
All statistical analyses were performed by R (version 3.6.1). A p value less than 0.05 was indicative of statistical significance.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| sodium bicarbonate group | – | Drug: sodium bicarbonateSodium bicarbonate was initiated within 48 hours after ICU admission. |
| non-sodium bicarbonate group | – | –Patients were not infused with sodium bicarbonate. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- We obtained data from the MIMIC-III. The newest version of MIMIC-III, v. 1.4, integrates 61,532 patients admitted to the ICUs of Beth Israel Deaconess Medical Center in Boston, Massachusetts.
Key inclusion criteria (1 listed)
- (1) pH≤7.3; (2) BE≤-8, or HCO3- < 20 mmol/L if BE was missing; and (3) PaCO2< 50 mmHg, or without chronic obstructive pulmonary disease (COPD) in discharge diagnoses if PaCO2 was unavailable.
Key exclusion criteria (1 listed)
- (1) age 16 or under; (2) diabetes insipidus ; (3) comorbidity of peripheral paralysis; (4) ICU stay over 100 days; (5) SBT was initiated before ICU admission , later than 48 hours after ICU admission or after a record of order for renal replacement therapy (RRT); and (6) death within the first 24 hours after ICU admission.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sodium bicarbonateDrug exposure | Drug | sodium bicarbonate group |
Primary outcome
newly developed or exacerbated organ dysfunction
Time frame: The duration of the database covers from June 2001 to October 2012.
We defined a composite of newly "developed or exacerbated organ dysfunction" (d/eOD) as a net increase in Sequential Organ Failure Assessment (SOFA) score ≥2 of at least one organ within 7 days of ICU admission over the baseline (SOFA score in the first 24 hours).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2021.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Metabolic Acidosis; Critically Ill Patients; Organ Dysfunction, run by Peking University Third Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
newly developed or exacerbated organ dysfunction (time frame: The duration of the database covers from June 2001 to October 2012.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2021; AzTrials last refreshed its copy on 30 Oct 2026.